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Abstract
Diamond–Blackfan anemia (DBA) is a rare genetic hypoplasia of erythroid progenitors characterized by mild to severe anemia and associated with congenital malformations. Clinical manifestations in DBA patients are quite variable and genetic testing has become a critical factor in
establishing a diagnosis of DBA. The majority of DBA cases are due to heterozygous loss-offunction mutations in ribosomal protein (RP) genes. Causative mutations are fairly straightfor-
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#01GM1301, 01GM1609); ERC (261178).

ward to identify in the case of large deletions and frameshift and nonsense mutations found

∗ Steven R. Ellis and Irma Dianzani contributed

observed that defective pre-rRNA processing, a hallmark of the disease, was rescued by lentivi-

equally to this work.

ral vectors expressing wild-type RPS19. Here, we use this complementation assay to determine

Communicated by Maurizio Genuardi

whether RPS19 variants of unknown significance are capable of rescuing pre-rRNA process-

early in a protein coding sequence, but diagnosis becomes more challenging in the case of missense mutations and small in-frame indels. Our group recently characterized the phenotype of
lymphoblastoid cell lines established from DBA patients with pathogenic lesions in RPS19 and

ing defects in these lymphoblastoid cells as a means of assessing the effects of these sequence
changes on the function of the RPS19 protein. This approach will be useful in differentiating
pathogenic mutations from benign polymorphisms in identifying causative genes in DBA patients.
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1

INTRODUCTION

affected members of the same family. First-line therapy is steroid treatment; options in steroid-resistant patients are chronic transfusions

Diamond–Blackfan anemia (DBA) is a congenital disorder of the bone

or hematopoietic stem cell transplantation. DBA is usually caused by

marrow characterized by normochromic macrocytic anemia and asso-

heterozygous mutations in ribosomal protein (RP) genes that lead to

ciated with physical malformations and increased risk of malignancies

haploinsufficiency. To date, mutations in 19 RP genes (RPS19, RPS24,

(Lipton & Ellis, 2009; Vlachos et al., 2008). The penetrance is incom-

RPS17, RPL35A, RPL5, RPL11, RPS7, RPS10, RPS26, RPL26, RPL15,

plete and a wide range of clinical manifestations may occur even among

RPL31, RPS29, RPS28, RPL27, RPS27, RPS15A, RPL35, RPL18) have been

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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identified in DBA patients (Cmejla, Cmejlova, Handrkova, Petrak, &

since the patient could simultaneously carry a disease-causing muta-

Pospisilova, 2007; Doherty et al., 2010; Draptchinskaia et al., 1999;

tion, responsible for the defective rRNA processing, in another RP

Farrar et al., 2008, 2014; Gazda et al., 2006, 2008, 2012; Gripp et al.,

gene.

2014; Ikeda et al., 2017; Landowski et al., 2013; Mirabello et al., 2014,

We recently characterized the phenotype of lymphoblastoid cell

2017; Wang et al., 2015). Rare mutations in GATA1, that abrogate the

lines (LCLs) established from DBA patients with loss-of-function muta-

production of the full-length protein (Parrella et al., 2014; Sankaran

tions in RPS19 (Aspesi et al., 2017). Aberrant pre-rRNA processing

et al., 2012), and in TSR2, encoding a RPS26 interactor (Gripp et al.,

and other pathological features were rescued by gene complementa-

2014), have also been described.

tion, using an RPS19 transgene carried by a lentiviral vector (Aspesi

In DBA, the deficiency of a RP leads to the reduction in the num-

et al., 2017). We reasoned that this complementation assay could be

ber of ribosomes and this is particularly harmful for the red cell

employed to investigate the effects of a wide range of VUS on RPS19

progenitors. Ribosome biogenesis is a complex process that requires

function (Figure 1). Here, we reviewed the literature regarding RPS19

the involvement of hundreds of different structural and accessory

mutations and selected a total of 12 RPS19 variants for functional

molecules. Mature 18S ribosomal RNA (rRNA), which forms the 40S

analysis.

subunit, together with mature 28S and 5.8S rRNAs, which are components of the 60S subunit, are all produced by sequential nucleolytic
cleavages of a large polycistronic 45S precursor. Mutations in RPs of

2

MATERIALS AND METHODS

the small (RPS) or large (RPL) ribosomal subunit affect various steps
of pre-rRNA maturation, resulting in the impairment of ribosome biogenesis and function. Since the alterations of pre-rRNA processing
cause the accumulation of specific rRNA precursors depending on the
mutated RP gene (Boria et al., 2010; Farrar et al., 2014; Flygare et al.,
2007), pre-rRNA analysis has been proposed as a potential aid for making a DBA diagnosis (Farrar et al., 2014; Quarello et al., 2016). RPS19
haploinsufficiency affects the maturation of 40S ribosomal subunits by
specifically affecting the conversion of 21S pre-rRNA into 18SE pre-

2.1

Cells

LCLs were established as described previously from two DBA patients
(P1 and P2) and one healthy subject (C), after approval of the local
ethics committee (Aspesi et al., 2017). Both patients had a heterozygous loss-of-function mutation in RPS19 and their genotypes were: P1:
c.283_284delG, p.Gly95Alafs*16; P2: c.36_37insAG, p.Glu13Argfs*17
(RefSeq NG_007080.3, NM_001022.3, NP_001013.1). Cells were
maintained in RPMI 1640 medium supplemented with 10% fetal

rRNA (Choesmel et al., 2007; Flygare et al., 2007), thus leading to accu-

bovine serum and antibiotics (100 U/ml penicillin and 100 𝜇g/ml strep-

mulation of 21S pre-rRNA and increase of 21S/18SE ratio.

tomycin) and were incubated at 37◦ C in a humidified atmosphere with

While many of the mutations found in RP genes are nonsense,
frameshift, and splice site mutations that can be easily interpreted as
pathogenic based on their predicted effects on the expression of a protein, the pathogenicity of missense variants remains often controversial. Over 25% of all DBA patients’ mutations are found in RPS19 and

5% CO2 .

2.2 Selection of variants for the complementation
assay

more than 40 different missense mutations and small in-frame indels

From the list of 165 RPS19 mutations described in the literature,

have been described in this gene (Boria et al., 2010; Konno et al., 2010;

we excluded protein-truncating variants, that is, variants predicted to

Ozono et al., 2016; Smetanina et al., 2015; Wang et al., 2015). Their

lead to nonsense-mediated decay (NMD) and expected to have severe

pathogenic significance is often difficult to evaluate and may present

effects on gene function, as well as variants that disrupt a canonical

an obstacle to genetic testing of the proband as well as of family mem-

splice site. For the present analysis, we considered only VUS: missense

bers who are silent carriers of the disease. This is particularly rele-

variants, small in-frame indels, and truncating variants located in the

vant when trying to identify a suitable donor for hematopoietic stem

last or penultimate exon. Stop codons located in the penultimate exon

cell transplantation. To be able to counsel patients in these families,

less than 50–55 bases from the final intron are not supposed to cause

it is necessary to fully understand the role played by these variants of

NMD (Le Hir, Izaurralde, Maquat, & Moore, 2000), thus the three non-

unknown significance (VUS) on protein expression and function.

sense variants in our list (c.376C>T p.Gln126*, c.382C>T p.Gln128*,

In silico tools can aid in the interpretation of VUS and rely on the

c.406G>T p.Gly136*) could theoretically produce truncated proteins.

following criteria: (i) absence or very low frequency of the variant in

We chose to select for the complementation assay only the variant

the general population, (ii) change of an evolutionary conserved codon,

located closest to the 3′ end of the transcript, c.406G>T p.Gly136*.

(iii) non-conservative amino acid substitution, (iv) cosegregation of the
variant with the disease phenotype in the family under study (Richards

The novel variant c.338_340delTGG p.Val113del was submitted to
the DBA database LOVD v.2.0 Build 36 (Boria et al., 2008, 2010).

et al., 2015). However, it is not recommended to use these predictions

To predict the functional consequences of variants, we used the

as the sole source of evidence to reach a diagnostic conclusion, and

following in silico prediction tools: SIFT v.1.03, Polyphen-2 (Polymor-

functional studies should support the in silico results. A VUS in RPS19

phism Phenotyping v2), Provean v1.1.3, Condel 2.0, Mutation Assessor

can be classified as benign when the analysis of rRNA maturation in

release 3, and MutationTaster 2. Mutation Assessor evaluates the

patient cells points to defects in a different gene. On the contrary, the

probability that a mutation affects protein function, therefore the

observation of pre-rRNA processing alterations consistent with RPS19

output “low” indicates a neutral variant. For Condel, the score ranges

loss of function, is not sufficient to interpret the VUS as pathogenic,

from 0 (neutral) to 1 (damaging); all variants we studied had an output

1104
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F I G U R E 1 Scheme of the complementation assay. Cells from DBA patients have a loss-of-function mutation in RPS19 that cause the accumulation of 21S rRNA. Expression of either wild-type RPS19 or RPS19 with a benign sequence variant allows the rescue of the rRNA processing defect.
On the contrary, expression of a RPS19 transgene carrying a deleterious mutation does not recover the pathological phenotype

between 0.5 and 0.9 and we considered them “probably damaging.”
To address the potential effects on gene splicing, we used GeneSplicer,
Human Splicing Finder version 3.1, MaxEntScan, NetGene2 version
2.42, NNSplice version 0.9, and FSPLICE. The presence and frequency
of VUS selected for the complementation assay were evaluated in
population databases: 1000 Genomes, Genome Aggregation Database
(GnomAD), Exome Variant Server (EVS), and Exome Aggregation
Consortium (ExAC).

2.4

Complementation assay

Site-directed mutagenesis on RPS19 cDNA was carried out to introduce the selected variants using the QuikChange Site directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). Primers are
available upon request. The presence of each mutation was confirmed
by Sanger sequencing. Lentiviral vectors were produced after transient transfection of 293T cells with the third generation packaging
plasmids (pMDLg/pRRE, pRSV-REV, and pMD2-VSVG) and with the
transfer construct for each RPS19 transgene (Aspesi et al., 2014; Fol-

2.3

Websites

lenzi, Ailles, Bakovic, Geuna, & Naldini, 2000). One control (C) and two
RPS19-haploinsufficient LCLs (P1 and P2) were transduced with 10

DBA database, https://www.dbagenes.unito.it/home.php

multiplicity of infection to express the mutant RPs. Integration and

SIFT, https://sift.jcvi.org

expression of at least one copy of the cassette carrying both RPS19

Polyphen-2, https://genetics.bwh.harvard.edu/pph2

and green fluorescence protein (GFP) sequences resulted in the emis-

Provean, https://provean.jcvi.org/index.php

sion of green fluorescence. GFP+ cells were sorted, recultured for 2–

Condel, https://bbglab.irbbarcelona.org/fannsdb/

3 weeks and analyzed. Total RNA was isolated using TRIzol Reagent

Mutation Assessor, https://mutationassessor.org

(Invitrogen, Carlsbad, CA, USA), followed by on-column DNase treat-

MutationTaster, https://www.mutationtaster.org

ment and purification with miRNeasy Mini Kit (Qiagen, Milano, Italy).

GeneSplicer, https://www.cbcb.umd.edu/software/GeneSplicer/gene_
spl.shtml

For Northern blot analysis, 5 𝜇g of total RNA was fractionated on 1.5%
formaldehyde agarose gels, transferred to a positively charged nylon

Human Splicing Finder, https://www.umd.be/HSF

membrane (Roche, Monza, Italy) and immobilized on the membrane

MaxEntScan, https://genes.mit.edu/burgelab/maxent/Xmaxentscan_

by UV-crosslinking performed with 120 milliJoules/cm2 . The oligonu-

scoreseq.html

cleotide probe (5′ -CCTCGCCCTCCGGGCTCCGTTAATGATC-3′ ) was

NetGene2, https://www.cbs.dtu.dk/services/NetGene2

labeled with [𝛾-32 P]ATP using T4 polynucleotide kinase and hybridized

NNSplice. https://www.fruitfly.org/seq_tools/splice.html

overnight with the membrane at 37◦ C in ULTRAHyb-Oligonucleotide

FSPLICE, https://www.softberry.com/berry.phtml?topic=fsplice&gro

hybridization buffer (Ambion, Thermo Fisher Scientific, Waltham, MA,

up=programs&subgroup=gfind

USA). The membrane was washed at 37◦ C with 6XSSC and subjected

1000 Genomes, https://www.internationalgenome.org/

to phosphorimaging analysis (Flygare et al., 2007). The overexpression

GnomAD, https://gnomad.broadinstitute.org/

of RPS19 did not cause adverse effects on pre-rRNA processing in con-

EVS, https://evs.gs.washington.edu/EVS/

trol cells (Aspesi et al., 2017), nor did the expression of RPS19 mutants

ExAC, https://exac.broadinstitute.org/

(Figure 2A).

ASPESI ET AL .
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F I G U R E 2 Complementation assay on VUS reported in DBA patients. A: Representative Northern blot experiments. Patient cells have an
increased 21S/18SE rRNA ratio, that is corrected by the expression of a wild-type RPS19 transgene but not by the expression of RPS19 carrying a pathogenic mutation. Upper panels show Northern blotting, lower panels show corresponding RNA gels stained by a fluorescent nucleic acid
dye. C: control, P1: patient 1, P2: patient 2. B: Densitometry quantification of 21S/18SE ratio calculated on repeated Northern blot experiments.
Asterisks represent statistically significant differences (P < 0.05) between samples with wild-type and mutant exogenous RPS19. Error bars represent standard error of the mean

2.5

Quantitative RT-PCR

RNA isolated from cells with wild-type or mutant exogenous RPS19
was reverse transcribed using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA). Real-time
PCR amplification of cDNA was performed in triplicate using Power
R Green PCR Master Mix (Applied Biosystems) and specific
SYBR

primers for the target genes RPS19 and CDKN1A (p21). ACTB (𝛽-actin)
was used as reference gene.

recently and now have a total of 165 different RPS19 mutations
reported in 313 DBA patients (Arbiv et al., 2017; Chae et al., 2010,
2014; Da Costa et al., 2013; Delaporta et al., 2014; Errichiello et al.,
2017; Farrar et al., 2011; Gerrard et al., 2013; Ichimura et al., 2017;
Konno et al., 2010; Kuramitsu et al., 2012; Landowski et al., 2013;
Ozono et al., 2016; Pospisilova et al., 2012; Quarello et al., 2012;
Smetanina et al., 2015; Solomon et al., 2014; Tsangaris et al., 2011;
van Dooijeweert et al., 2017; Wang et al., 2015; Zhang et al., 2016).
For our study, we selected only those variants for which there was
no strong evidence of pathogenicity according to the genetic crite-

2.6

Statistical analysis

ria outlined in Materials and Methods, and obtained 47 VUS reported
in 122 patients (39% of RPS19-mutated patients, approximately 10%

Northern blot bands were quantified using the ImageJ software.

of all DBA patients). We also included a new previously unpublished

Results from P1 and P2 patient cells were considered as biological

variant we identified in a DBA patient by next-generation sequenc-

replicates. Differences in mean values between samples with either

ing, c.338_340delTGG p.Val113del (Supp. Table S1). Thirteen of the

wild-type or mutant exogenous RPS19 were analyzed with the Mann–

VUS have already been found to be pathogenic by published functional

Whitney test for two-tailed data. Statistical significance was defined by

studies (Angelini et al., 2007; Badhai et al., 2009; Chatr-Aryamontri

a P value ≤0.05.

et al., 2004; Chae et al., 2014; Choesmel et al., 2007; Cmejlova et al.,
2006; Da Costa et al., 2003; Gazda et al., 2004; Hamaguchi et al., 2002;
Idol et al., 2007;) (Supp. Table S1) and so were not tested in our study.

3

RESULTS

The VUS were analyzed by multiple in silico tools to predict the
impact of sequence variants on protein function. Five missense

Selection of variants and in silico analyses

variants that were analyzed were considered tolerated/benign by at

The DBA database (Boria et al., 2008, 2010) included 129 RPS19 muta-

as to whether or not they could be the pathogenic lesion in these

tions in 219 patients at its last update in 2010. We reviewed the

patients. These were all selected for functional analysis using the

literature to collect additional RPS19 mutations identified more

complementation assay outlined here (Table 1). We also chose to

3.1

least one of the six in silico tools indicating some degree of ambiguity
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TA B L E 1

VUS in RPS19 identified in DBA patients selected for complementation assay

DNA
change

Protein
change

Mutation
taster

Mutation
assessor

c.1A>G

p.Met1?

Disease
causing

c.62T>C

p.Phe21Ser

c.187_189
insCAC

Affected
patients

Polyphen-2

Provean

SIFT

Condel

na

Probably
damaging

Neutral

Damaging

Probably
damaging

5

Disease
causing

Medium

Probably
damaging

Deleterious

Tolerated

Probably
damaging

1

p.His63dup

Disease
causing

na

na

Deleterious

na

na

1

c.281G>T

p.Arg94Leu

Polymorphism

Medium

Benign

Deleterious

Tolerated

Probably
damaging

1

c.305G>C

p.Arg102Pro

Disease
causing

Medium

Benign

Deleterious

Damaging

Probably
damaging

1

c.353A>G

p.Asp118Gly

Disease
causing

Low

Benign

Deleterious

Tolerated

Probably
damaging

1

c.406G>T

p.Gly136*

Disease
causing

na

na

na

na

na

1

c.338_340
delTGG

p.Val113del

Disease
causing

na

na

Deleterious

na

na

1

na, not available. RefSeq: NM_001022.3, NP_001013.1.
Numeric output data are shown in Supp. Table S1. Websites and software versions are reported in the Materials and Methods section.

study a nonsense VUS late in the coding sequence predicted to escape

RT-PCR (Supp. Figure S1A); Sanger sequencing performed on cDNA

nonsense-mediated mRNA decay (Le Hir et al., 2000) as well as two

demonstrated the presence of the mutated transcripts (Supp. Figure

small in-frame indels, whose impact could not be determined by most

S1B). Processing of pre-rRNAs was evaluated by Northern blotting

prediction algorithms (Table 1). As negative controls for the effect of

and results obtained by expressing wild-type or mutant transgenes

known loss-of-function mutations, we chose a nonsense mutation,

were compared. Representative experiments are shown in Figure 2A.

c.166C>T p.Arg56*, previously reported in four DBA patients (Boria

Patient cells with no exogenous RPS19 (i.e., parental cells) or with the

et al., 2010; Proust et al., 2003; Willig et al., 1999) and the missense

negative control p.Arg56* RPS19 had a mean 21S/18SE rRNA ratio

c.178A>C p.Thr60Pro, reported in one patient and predicted as dam-

of 2.97 ± 0.21 (standard deviation, SD) and 2.69 ± 0.31, respectively,

aging by every in silico tool we used. None of the variants chosen for

whereas patient cells expressing the wild-type transgene had a ratio of

functional analysis here were reported in 1000 Genomes, GnomAD,

1.20 ± 0.11, similar to the value of cells from healthy donors, that was

EVS, and ExAC.

1.13 ± 0.13 (Figure 2A and B). Densitometry of Northern blots (Fig-

Finally, we assessed whether the VUS we selected caused the cre-

ure 2B) showed statistically significant differences (P < 0.05) between

ation or loss of splice sites by in silico tools. These prediction tools have

samples with wild-type and mutant exogenous RPS19, demonstrating

low specificity (∼60%–80%), but quite high sensitivity (∼90%–100%)

that all tested VUS were unable to recover the pathogenic pheno-

in predicting splice site abnormalities, and therefore have a low false

type of RPS19-deficient cells. The only exception was c.281G>T

negative rate (Houdayer et al., 2012; Richards et al., 2015). None

p.Arg94Leu (mean 21S/18SE ratio 1.43 ± 0.12), which showed no

of the VUS included in this study were predicted to affect splicing,

statistical difference from wild-type RPS19.

but the variant c.353A>G that, according to Human Splicing Finder,

According to our data, we propose an arbitrary 21S/18SE cut-off

MaxEntScan, and FSPLICE, could activate a cryptic donor splice site

value ≥2 to define pathogenicity and ≤1.5 to indicate normal protein

(data not shown).

function. None of the mutants we analyzed showed a 21S/18SE ratio
between these two values.

3.2

Analysis of VUS by complementation assay

Our previous findings showed that transfection of RPS19haploinsufficient LCLs with a vector expressing RPS19 cDNA

3.3 Analysis of variants found in population
databases

corrected the abnormal accumulation of 21S pre-rRNA, a well-

Population databases such as 1000 Genomes, GnomAD, EVS, and

established defect in ribosome biogenesis caused by the loss of RPS19

ExAC were searched for polymorphisms in RPS19 that cause missense

function. Ribosome biogenesis defects such as these have been a

substitutions. Overall amino acid changes in RPS19 were extremely

hallmark of DBA pathogenesis in patients harboring mutations in

rare in population databases. No missense variant was present in

RP genes. To assess the function of individual variants selected, we

1000 Genomes, which includes data from more than 5,000 healthy

asked whether the variants could rescue the pre-rRNA processing

subjects. The two most common variants in GnomAD, EVS, and ExAC,

defect in the complementation assay outlined in Figure 1. Cells

were c.68A>G p.Lys23Arg and c.164C>T p.Thr55Met (Table 2). These

expressing the mutant transgenes showed an increased level of RPS19

variants are presumed to be benign since it seems unlikely that individ-

transcript compared to parental cells, as measured by quantitative

uals included in these databases would have a rare disease like DBA.
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TA B L E 2

VUS in RPS19 selected from population databases
Population database (MAF)

DNA
change

Protein
change

1000
genomes

c.68A>G

p.Lys23Arg Not
0.0001292 0.0001895 0.0002071 Disease
Medium
Benign
Deleterious Damaging
Probably
reported
causing
score 2.29 score 0.097
score
score 0.03 damaging
score 26
−2.601
score
0.617

GnomAD

ExAC

EVS

Mutation Mutation
taster
assessor

Polyphen-2 Provean

c.164C>T p.Thr55Met Not
0.0002261 0.0002734 0.0002478 Disease
Medium
Possibly
Neutral
reported
causing
score 2.08 damaging
score
score 81
score 0.926
−1.889

SIFT

Condel

Tolerated
Probably
score 0.06 damaging
score
0.647

MAF, minor allele frequency. RefSeq: NM_001022.3, NP_001013.1.
Mutation Taster: the score for amino acid substitutions reflects the physicochemical difference between the original and the mutated amino acid but does
not influence the prediction. Mutation Assessor: the Functional Impact score is reported. PROVEAN: a score equal to or below the predefined threshold
(−2.5) predicts a deleterious effect for the protein variant; a score above the threshold indicates that the variant is predicted to have a neutral effect. SIFT:
the score predicts whether an amino acid substitution affects protein function, and ranges from 0.0 (deleterious) to 1.0 (tolerated).
Websites and software versions are shown in the Materials and Methods section.

F I G U R E 3 Complementation assay on VUS found in population databases. A: Representative Northern blot experiment. Upper panel shows
Northern blot, lower panel shows the corresponding RNA gel stained by a fluorescent nucleic acid dye. C: control, P1: patient 1, P2: patient 2.
B: Densitometry quantification of 21S/18SE ratio shows that neither variant could rescue the defective rRNA processing in patients cells. Asterisks represent statistically significant differences (P < 0.05) between samples with wild-type and mutant exogenous RPS19. Error bars represent
standard error of the mean

Interestingly, variants c.68A>G p.Lys23Arg and c.164C>T p.Thr55Met

malize the level of p21, but the expression of mutant p.Arg94Leu led to

were predicted to be benign only by one out of six and two out of

a clear, though not significant, decrease of p21 (Figure 4). Interestingly,

six bioinformatic tools, respectively. Northern blot analysis showed

the high p21 levels measured for the VUS p.Lys23Arg and p.Thr55Met

that these variants failed to rescue the pre-rRNA processing defects

corroborate their interpretation as deleterious variants (Figure 4).

in patient lymphoblasts (Figure 3A). The mean 21S/18SE ratios for
variants p.Lys23Arg and p.Thr55Met were 2.09 ± 0.13 and 2.01 ± 0.07,
respectively, and were significantly different from data obtained by the

4

DISCUSSION

wild-type transgene, suggesting that these amino acid substitutions
impair, at least partially, protein function (Figure 3A and B).

Our work was aimed at creating a complementation assay to assess the
function of RPS19 VUS and clarify their involvement in the pathogen-

3.4

Evaluation of p21 transcript level

esis of DBA. Novel sequence variants in genes known to be involved
in DBA have been increasingly detected, but our understanding of the

RPS19 deficiency induces stabilization of p53 and increased level of its

clinical significance of these novel variants is often limited. Many of

target p21; such alterations are recovered by expression of the RPS19

the most challenging variants change only one amino acid, making it

transgene (Aspesi et al., 2017). We performed quantitative RT-PCR

difficult to discern benign variants from pathogenic mutations that

to measure the level of p21 transcript in patient cells expressing the

disrupt protein function. In silico prediction tools can be of aid in

mutant transgenes. The results validated the data obtained by North-

the interpretation of sequence variants but their output should be

ern blot analysis, since the expression of RPS19 mutants could not nor-

validated by functional studies.
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F I G U R E 4 Level of p21 transcript in patient cells expressing wild-type or mutant RPS19. The increased level of p21 typical of DBA patient cells is
corrected by the expression of a wild-type RPS19 transgene but not by the expression of RPS19 carrying a pathogenic mutation. Results obtained
by quantitative RT-PCR performed on P1 and P2 patient cells were considered biological replicates. Asterisks represent statistically significant
differences between samples with wild-type and mutant exogenous RPS19: *P < 0.05; **P < 0.01. Error bars represent standard error of the mean

It is widely accepted that the underlying pathophysiology in

missense c.281G>T p.Arg94Leu successfully rescued the rRNA pro-

the majority of DBA patients is haploinsufficiency for a RPs and

cessing defect in patient cells. This variant was reported as pathogenic

an ensuing disruption of ribosome biogenesis. RPS19 is the most

after the identification in a female DBA patient whose parents were

frequently mutated gene in DBA and structure/function relation-

not tested (Boria et al., 2010). Our results suggest that this variant

ships of known pathogenic mutations have been characterized pre-

may actually be benign and further studies should be carried out in

viously. The crystal structure of RPS19 from the archeon Pyroccocus

this patient to establish the causative gene. The remaining variants

abyssi was used to group RPS19 missense mutations in two classes:

c.1A>G p.Met1?, c.62T>C p.Phe21Ser, c.187_189insCAC p.His63dup,

class I included residues essential for the folding and stability of

c.305G>C p.Arg102Pro, c.353A>G p.Asp118Gly and c.406G>T

the protein, whereas class II included mutations that affected sur-

p.Gly136* were not able to complement RPS19 deficiency. Among the

face residues and presumably impaired the capacity of RPS19 to

variant failing to complement was the new variant c.338_340delTGG

engage intermolecular interactions (Gregory et al., 2007). In another

p.Val113del, whose impact was difficult to predict even by bioinfor-

study, eleven missense mutations and one trinucleotide insertion

matic algorithms.

were expressed in human HEK293 cells (Angelini et al., 2007). Some

The most surprising result from our analysis was that two rare

mutants, corresponding to class I mutants (p.Val15Phe, p.Leu18Pro,

variants selected from population databases, c.68A>G p.Lys23Arg,

p.Ala57Pro, p.Ala61Glu, p.Gly127Glu, and p.Leu18_Ala19insGlu) were

and c.164C>T p.Thr55Met failed to complement the pre-rRNA pro-

expressed at a barely detectable level, whereas the others (all

cessing defect in patient lymphoblasts. The latter variant was previ-

class II mutants: p.Pro47Leu, p.Trp52Arg, p.Arg56Gln, p.Arg62Gln,

ously observed in a DBA patient who also carried a second variant,

p.Arg62Trp, p.Arg101His), although more stable, were not assembled

p.Val15Phe, on the same allele. In this case, p.Val15Phe was considered

into mature ribosomes.

pathogenic, whereas p.Thr55Met was interpreted as benign because

Additional studies have shown that missense mutations can influence the localization of RPS19 and disrupt function by mislocalization.

only protein localization was being studied (Boria et al., 2008; Da Costa
et al., 2003).

For example, mutant proteins such as p.Val15Phe, p.Gly127Gln, and

There is growing evidence that RP mutations can be found in

p.Leu131Pro could not reach the nucleolus and their expression was

patients with very mild or absent hematologic manifestations, as

dramatically decreased compared with the wild-type protein (Cretien

previously described, for instance, in a family with no sign of DBA

et al., 2008; Da Costa et al., 2003).

where a truncating germline mutation in RPS20 cosegregated with

Because of the limitations associated with assessing a protein's

colon cancer (Nieminen et al., 2014). This is also supported by the

function based on sequence analysis alone, there is a significant need

recent report of two unrelated patients with congenital heart dis-

to be able to functionally annotate novel sequence variants for their

ease and mutations in RPS24 who were not anemic (Vlachos et al.,

potential involvement in DBA pathogenesis. We have developed a new

2018). Our observation that VUS reported in population databases

complementation assay to assess a variant's function based on its abil-

could be involved in DBA pathogenesis highlights the need to

ity to rescue a pre-rRNA processing defect in lymphoblasts derived

deepen our knowledge about the possible presence in the general

from patients haploinsufficient for RPS19. This assay is not restricted

population of silent carriers of RP mutations and atypical cases

to RPS19 and could potentially be developed for other known DBA

of DBA.

genes.

Our results also emphasize the limited reliability of in silico tools for

We functionally tested 12 variants: nine were already described

pathogenicity prediction. According to the data obtained by our com-

in the literature as mutations responsible for DBA, one was a new

plementation assay, Mutation Taster was the only tool with sensitivity

variant we identified in a DBA patient and two variants were selected

and specificity equal to 1, whereas the other tools resulted in false neg-

from population databases. Among the variants we analyzed, only the

ative and/or false positive predictions.
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Several VUS have been reported also in other RP genes mutated
in DBA patients (Arbiv et al., 2017; Doherty et al., 2010; Gerrard
et al., 2013; Konno et al., 2010; Pospisilova et al., 2012; Smetanina
et al., 2015; Tsangaris et al., 2011; van Dooijeweert et al., 2017). In the
future, appropriate complementation assays could be implemented to
extend the study of pathogenicity to other DBA genes, similarly to the
approach we developed for RPS19.
In conclusion, we provided a strategy to distinguish disease-causing
mutations in RPS19 from benign polymorphisms and clarify their clinical significance. This information should assist clinicians in the counseling and management of DBA patients and their families.
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